Literature DB >> 8640753

Vascular and perivascular GD3 expression in human glioma.

S Koochekpour1, G J Pilkington.   

Abstract

A major hallmark of gliomas is their intense neovascularisation. Ganglioside GD3, is one of the major gangliosides which has been implicated in tumour angiogenesis. Recently we reported that GD3 was a potent stimulator of vascular endothelial growth factor release in human glioma cell lines. In the present study we were able to detect GD3-immunoreactivity in 10 out of 10 cases of glioblastoma multiforme and 7 out of 10 cases of anaplastic astrocytoma while low grade tumours were negative. Interestingly, GD3 was intensively expressed in hypervascularised areas of high grade gliomas. These data support the involvement of this ganglioside in brain tumour angiogenesis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8640753     DOI: 10.1016/0304-3835(96)04231-0

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  4 in total

1.  Ganglioside GM3 Is Antiangiogenic in Malignant Brain Cancer.

Authors:  Thomas N Seyfried; Purna Mukherjee
Journal:  J Oncol       Date:  2010-06-20       Impact factor: 4.375

2.  Interaction of fibroblast growth factor-2 (FGF-2) with free gangliosides: biochemical characterization and biological consequences in endothelial cell cultures.

Authors:  M Rusnati; E Tanghetti; C Urbinati; G Tulipano; S Marchesini; M Ziche; M Presta
Journal:  Mol Biol Cell       Date:  1999-02       Impact factor: 4.138

3.  Hepatocyte growth factor production is stimulated by gangliosides and TGF-beta isoforms in human glioma cells.

Authors:  Sheng-hua Chu; Yan-bin Ma; Hong Zhang; Dong-fu Feng; Zhi-an Zhu; Zhi-qiang Li; Xian-hou Yuan
Journal:  J Neurooncol       Date:  2007-04-27       Impact factor: 4.130

Review 4.  Ganglioside GD3 synthase (GD3S), a novel cancer drug target.

Authors:  Jinyi Liu; Xiangjin Zheng; Xiaocong Pang; Li Li; Jinhua Wang; Cui Yang; Guanhua Du
Journal:  Acta Pharm Sin B       Date:  2018-07-25       Impact factor: 11.413

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.